Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DehydraTECH-tirzepatide
- Development stage
- Preclinical
- Lead developer
- Lexaria Bioscience
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
DehydraTECH-tirzepatide is an oral formulation of the dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, being developed by Lexaria Bioscience and its subsidiary Cannabis Delivery Sciences. The formulation utilizes Lexaria's proprietary DehydraTECH drug delivery technology, which is designed to enhance the bioavailability, speed of onset, and brain penetration of bioactive compounds by improving their absorption through the gastrointestinal tract. By enabling effective oral delivery of tirzepatide—which is typically administered via subcutaneous injection—this candidate aims to provide a more convenient treatment option for patients with type 2 diabetes, obesity, and related metabolic conditions such as metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and sleep apnea. The program is currently in the preclinical stage, with ongoing studies evaluating its pharmacokinetic profile compared to existing injectable and oral GLP-1 therapies.
- Other names
- Oral tirzepatide (Lexaria)DehydraTECH-GLP-1DehydraTECH-GLP1DehydraTECH-GLP 1
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on DehydraTECH-tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DehydraTECH-tirzepatide.